manganese chloride
Small moleculeapproved
Approved
Jun 26, 1986
Manganese Bromide is a highly water soluble crystalline salt composed of manganese and bromine with the formula MnBr2. Manganese Bromide can be used in place of palladium in the Stille reaction, which couples two carbon atoms using an organotin compound — NCATS
Clinical trial activity
8 trials · 4 clinical orgs · 3 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Sep 1, 2017 (NCT02393183)
Timeline
Indications
Approved for
Mechanism of action
- ElectrolyteSupplementation
Electrolyte supplementation
Approval history
- approvedPriority reviewJun 26, 1986
- approvedJan 1, 1800
Chemistry & pharmacology
Loading structure…
SMILES
[Cl-].[Cl-].[Mn+2]- Mol. weight
- 125.84 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1200693 ↗
- WikipediaManganese(II) chloride ↗
- NCATSH6EP7W5457 ↗
- ChEMBLCHEMBL5314371 ↗
- ChEMBLCHEMBL1200548 ↗
- WikipediaManganese ↗
Also known as
- lumenhance
- lumenhance
- lumenhance
- manganese chloride
- manganese chloride
- manganese chloride
- manganese chloride
- manganese chloride
- manganese chloride
- manganese chloride
- manganese chloride, 52mn-labeled
- manganese chloride, diammoniate
- manganese chloride, dihydrate
- manganese chloride, hexaammoniate
- manganese chloride, hexahydrate
- manganese chloride (mncl2)
- manganese chloride, monoammoniate
- manganese chloride tetrahydrate
- manganese chloride tetrahydrate
- manganese chloride tetrahydrate
- manganese chloride tetrahydrate
- manganese chloride tetrahydrate
- manganese chloride, tetrahydrate
- manganese dichloride
- manganese dichloride
- manganous chloride
- manganous chloride
- mncl2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04873440 | Phase 1/Phase 2 (Phase 2) | May 6, 2021 | People's Liberation Army of China |
| NCT04119843 | Phase 3 | Nov 30, 2019 | Ascelia Pharma AB, Humboldt University |
| NCT04004234 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2019 | People's Liberation Army of China |
| NCT03989310 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2019 | People's Liberation Army of China |
| NCT03989336 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2019 | People's Liberation Army of China |
| NCT03991559 | Phase 1 | Nov 1, 2018 | People's Liberation Army of China |
| NCT02393183 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2017 | Isfahan University |
| NCT02422368 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2017 | Isfahan University |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| People's Liberation Army of China | Government | 5 | 5 | 2 | 2018 |
| Isfahan University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Ascelia Pharma AB | For profit | 1 | 1 | 1 | 2019 |
| Humboldt University | Academic/Hospital | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1